Haemonetics Corp
Q3 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: −0.06%.
Did HAE Beat Earnings? Q3 2026 Results
Haemonetics delivered a solid fiscal third-quarter beat, with adjusted EPS of $1.31 clearing the $1.25 consensus by 4.77% and revenue of $338.97 million topping estimates by 1.88%, even as reported sales slipped 2.8% year-over-year. The headline decline was largely a function of the ongoing wind-down of CSL Plasma disposable sales and the prior-year divestiture of the Whole Blood product line, which masked an underlying organic ex-CSL revenue gain of 7.5% and reflected the company's deliberate shift toward higher-margin offerings. That portfolio transformation showed up clearly in GAAP gross margin, which expanded to 59.7% from 55.5% a year ago, helping lift adjusted operating margin to 26.3%. Free cash flow more than doubled to $74.20 million. A soft patch in Interventional Technologies, where revenue fell 11.4%, drew analyst attention, though management outlined targeted recovery steps including a planned U.S. launch of PerQseal Elite. Encouraged by the momentum, Haemonetics raised its full-year adjusted EPS guidance to $4.90-$5.00 and lifted its free cash flow outlook to $200-$220 million.
- Strong Plasma organic ex-CSL revenue growth of 20.2%
- Blood Management Technologies revenue growth of 8.3%
- Gross margin expansion driven by portfolio transformation to higher-margin offerings and product innovation
- Favorable working capital adjustments from lower inventory purchasing drove strong operating cash flow
- Continued transformation of product portfolio to higher margin offerings
“Third quarter revenue growth, margin expansion, and cash flow reflect the underlying strength of our core businesses. Blood Management Technologies and Plasma continue to drive our strong performance while we take targeted actions to reestablish momentum in Interventional Technologies and prepare for a US launch of PerQseal Elite. We are well positioned to finish the fiscal year strong and deliver our long-term growth and value creation objectives throughout our business.”
Haemonetics CEO, on the earnings call
Forward Guidance & Outlook
Haemonetics raised its fiscal 2026 guidance. Total company reported revenue is now expected to decline 1–3% (previously 1–4%), with organic ex-CSL revenue growth of 8–10% (previously 7–10%). By segment: Plasma reported growth of (2)–4%, organic ex-CSL 17–19%; Blood Center reported (16)–(18)%, organic 1–3%; Hospital reported ~4%, organic ~4%. Adjusted operating margin guidance was maintained at 26–27%. Adjusted EPS guidance was raised to $4.90–$5.00 from $4.80–$5.00. Free cash flow guidance was raised to $200M–$220M from $170M–$210M, with free cash flow to adjusted net income conversion now expected to exceed 80% (up from >70%).
HAE YoY Financials
HAE Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.